GlassScriptPhysician profile
Sean P Mulqueeny
NPI 1407871296
$44,775.14
in general payments reported to CMS, 2019-2025
25 companies · $993 in 2025
The $993 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,670 · 2021: $7,599 · 2022: $17K · 2023: $1,729 · 2024: $1,272 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,932 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,062.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23,795.29 | 2019-2022 | |
| Abbvie INC. | $6,619.81 | 2022-2025 | |
| Shire North American Group INC | $4,788.37 | 2019 | |
| Alcon Vision LLC | $4,628.77 | 2019-2025 | Precision 1, Tryptyr, Total30 |
| Oyster Point Pharma, INC. | $1,067.54 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $620.14 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $509.25 | 2022-2025 | Xiidra, Infuse, Miebo |
| Coopervision INC. | $457.47 | 2022-2025 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $398.32 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $300.20 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $264.87 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $241.61 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $184.39 | 2021-2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Kala Pharmaceuticals, INC. | $175.18 | 2019-2022 | |
| Amgen INC. | $148.30 | 2024-2025 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $117.33 | 2019-2022 | |
| Horizon Therapeutics Plc | $100.00 | 2023 | Tepezza |
| Dompe US, INC. | $84.25 | 2020-2025 | Oxervate |
| Harrow Eye, LLC | $71.16 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $58.48 | 2022-2025 | Omni Surgical System, Tearcare System |
| Biotissue Holdings INC. | $41.90 | 2019-2020 | |
| Lkc Technologies, INC. | $33.93 | 2025 | |
| Synergeyes, INC. | $27.00 | 2020 | |
| Aerie Pharmaceuticals, INC. | $21.23 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $20.35 | 2024 | Lipiflow System Activator (Disposable) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Mulqueeny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.